TRT Safety Monitoring
Overview
Polycythemia is the primary safety concern with testosterone replacement therapy. Elevated hematocrit (>54%) is an independent risk factor for MACE and VTE in men on TRT. This note provides the evidence-backed safety monitoring protocol and formulation selection framework for longevity-oriented coaching.
Hematocrit zones
| Zone | Hematocrit | Action |
|---|---|---|
| Normal | ≤0.48 | Standard monitoring |
| Elevated | 0.48–0.52 | Increase monitoring frequency; consider formulation switch |
| Polycythemia | 0.52–0.54 | Phlebotomy review; assess sleep apnea, hypoxia, vol status |
| Action required | >0.54 | Immediate clinical action; dose reduction or formulation switch to transdermal |
Mechanism: Testosterone increases renal EPO production and reduces hepcidin → enhanced iron bioavailability → elevated erythropoiesis → elevated hematocrit. Long-acting IM formulations carry the highest risk (~≥10% vs 1–5% with transdermal gels).
Baseline labs
Required before initiating any hormonal intervention:
| Lab | Assay note | Key threshold |
|---|---|---|
| Total testosterone | LC-MS/MS (not immunoassay) | <300 ng/dL + symptoms supports diagnosis |
| Free testosterone | Equilibrium dialysis | More accurate than analog assay in borderline cases |
| Estradiol | Sensitive assay (LC-MS/MS) | Low E2 (<15 pg/mL) also problematic |
| LH / FSH | — | Distinguishes primary vs secondary hypogonadism |
| SHBG | — | Modulates free T interpretation |
| Prolactin | — | Elevated prolactin suppresses gonadotropins |
| CBC with differential | Hematocrit baseline | Flag if >0.50 |
| PSA | — | Flag if >4.0; urology referral before initiating |
| Fasting glucose / HbA1c | — | Metabolic baseline |
| Lipid panel | — | TRT can suppress HDL; baseline needed |
| AST / ALT | — | Hepatotoxicity risk only with oral 17α-alkylated forms |
| Vitamin D | — | Often deficient; relevant for bone |
Monitoring intervals
| Parameter | Frequency |
|---|---|
| Hematocrit (CBC) | q3 months (titration phase); q6 months (stable) |
| Comprehensive hormone panel | q6 weeks after dose change; then q6–12 months |
| DEXA body composition | Annually (q6 months for granular feedback) |
| Lipid panel | Baseline; q6–12 months |
| PSA | q6–12 months |
| Blood pressure | Every visit (new FDA 2025 ABPM warning) |
| E2 (sensitive assay) | q6–12 months |
Formulation selection framework
Priority 1: Fertility desired
If the patient wants to preserve fertility:
- Recommended: hCG 250–500 IU SC 2–3x/week; Enclomiphene 12.5–25 mg/day
- Avoid: Testosterone enanthate/cypionate IM; standard testosterone gel
Priority 2: Hematocrit elevated (≥0.48)
Elevated baseline hematocrit or polycythemia history:
- Recommended: Transdermal gel 1% or 1.62% daily; SC testosterone enanthate 50–100 mg/week
- Avoid: IM testosterone enanthate/cypionate 200+ mg biweekly (supraphysiologic peaks)
Priority 3: High CV risk
Pre-existing cardiovascular disease (TRAVERSE population):
- Recommended: Transdermal gel 1% or 1.62% daily — lowest polycythemia risk
- Avoid: High-dose IM; supraphysiologic dosing
Priority 4: Oral preference
- Recommended: Jatenzo (testosterone undecanoate oral capsules) — FDA-approved 2019; requires fatty meal; 6.8% absolute bioavailability
- Avoid: Grey-market oral testosterone
Priority 5: Monthly adherence preference
- Recommended: Testosterone undecanoate IM (Nebido) 1000 mg Q10–14 weeks; ultra-long-acting
- Avoid: None
Default: Conservative weekly SC
- Testosterone cypionate or enanthate SC 50–100 mg/week
- Avoid 200–400 mg biweekly IM (supraphysiologic peaks)
Rationale: Weekly or more frequent low-dose SC flattens peak-trough fluctuation vs. biweekly IM. Preferred for longevity-oriented patients who want stable physiologic levels.
Safety flag summary
| Flag | Trigger | Action |
|---|---|---|
| HEMATOCRIT_CRITICAL | >0.54 | Immediate clinical action; consider dose reduction or switch to transdermal |
| PHLEBOTOMY_REVIEW | 0.52–0.54 | Assess vol status, sleep apnea, hypoxia |
| E2_ELEVATED | >40 pg/mL | Assess gynecomastia, water retention; consider dose reduction |
| E2_LOW | <15 pg/mL | Assess E2 deficiency symptoms; bone loss risk |
| PSA_ELEVATED | >4.0 | Urology referral; consider biopsy before continuing |
| BP_ELEVATED | >140/90 | New FDA 2025 warning; evaluate and manage |
| AF_HISTORY | Prior atrial fibrillation | Enhanced vigilance; TRAVERSE showed higher AF rate with TRT |
Blood pressure — FDA 2025 update
The FDA added a new blood pressure warning (February 2025) based on ABPM studies. Testosterone can increase blood pressure. Monitor BP at every visit. This applies to all formulations and routes of administration.
Drug interactions
| Drug | Effect |
|---|---|
| Warfarin | Potentiates anticoagulant effect; 2–5× increase in warfarin dose may be needed |
| Insulin / sulfonylureas | Enhanced insulin sensitivity → hypoglycemia risk; dose reduction may be needed |
| Corticosteroids | Additive fluid retention risk |
| 5α-reductase inhibitors (finasteride/dutasteride) | Reduce DHT conversion → shunting toward E2 aromatization → increased E2 |
Related notes
- Testosterone Optimization — hub note with full evidence overview
- Vitals Knowledge Map — cross-domain graph
- Cardiovascular risk — general cardiovascular risk context